Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 2

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.

World J Cardiol. Feb 26, 2026; 18(2): 114960
Published online Feb 26, 2026. doi: 10.4330/wjc.v18.i2.114960

Full Size Figure Download Figure

Figure 3 Integrated diagram of lipid and inflammation - targeting therapies. LDL: Low-density lipoprotein; PCSK9: Proprotein convertase subtilisin/kexin type 9; siRNA: Small interfering RNA; IL: Interleukin.

Citation: Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. World J Cardiol 2026; 18(2): 114960
URL: https://www.wjgnet.com/1949-8462/full/v18/i2/114960.htm
DOI: https://dx.doi.org/10.4330/wjc.v18.i2.114960

Write to the Help Desk

Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.